Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Curr Top Med Chem ; 23(7): 520-538, 2023.
Article in English | MEDLINE | ID: covidwho-20243928

ABSTRACT

Viral infections range from self-limiting to more serious and fatal infections; therefore, some viral infections are of great public health concern worldwide, e.g., Hepatitis B virus, Hepatitis C virus, and HIV. Recently, the world faced a new infection due to the coronavirus, COVID-19, which was announced as a pandemic in early 2020. This virus infected more than 500 million people, killing around 6 million people worldwide. On the other hand, the increase in drug-resistant strains is also creating serious health problems. Thus, developing new selective antiviral agents with a different mode of action to fight against mutated and novel viruses is a primary goal of many researchers. Taking into account the role of heterocyclic compounds in drug discovery as a key structural component of most of the bioactive molecules; herein, we report an extensive review of the antiviral activity of five-membered heterocyclic compounds reported from 2015 to date. In this review, the antiviral activities of the agents containing the specified ring systems thiadiazoles, triazoles, oxadiazoles, and thiazoles are discussed.


Subject(s)
COVID-19 , Heterocyclic Compounds , Thiadiazoles , Virus Diseases , Humans , Antiviral Agents/chemistry , Virus Diseases/drug therapy , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Thiadiazoles/chemistry
2.
Med Chem ; 19(8): 717-729, 2023.
Article in English | MEDLINE | ID: covidwho-2257282

ABSTRACT

Severe emergencies occurred across the globe, beginning with the outbreak of SARSCoV in 2002, followed by MERS-CoV in 2012. In December 2019, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China as the agent responsible for the recent COVID-19 pandemic outbreak. The virus rapidly spread throughout the world due to its high transmissibility, leading to enormous health problems and complexities. The COVID-19 pandemic has affected public health, the weak persons were severely affected by this virus. To stop the disease from spreading further, effective remedies are the need of the hour. Although SARS-CoV-2 vaccination campaigns are being carried out all over the globe, several new SARS-CoV-2 variants have emerged, and each has caused a wave of infections, highlighting an urgent need for therapeutics targeting SARS-CoV-2. Heterocyclic compounds have been explored extensively for a very long time for their biological activities, namely, anti-inflammatory, antimalarial, antitubercular, anticancer, antiviral, antimicrobial, antidiabetic, and many more bio-activities. Through this review, the author has tried to report the heterocyclic compounds synthesized all over the world over the last 2 years to fight against the SARS CoV-2 coronaviruses. The heterocyclic motifs mentioned in the review can serve as important resources for the development of COVID-19 treatment methods.


Subject(s)
COVID-19 , Heterocyclic Compounds , Humans , COVID-19/epidemiology , SARS-CoV-2 , Pandemics , COVID-19 Drug Treatment , COVID-19 Vaccines , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use
3.
Clin Lymphoma Myeloma Leuk ; 22(8): e716-e729, 2022 08.
Article in English | MEDLINE | ID: covidwho-1763647

ABSTRACT

INTRODUCTION: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during the COVID-19 pandemic, many of our patients received prolonged lenalidomide induction due to concerns about proceeding to ASCT. We investigated whether prolonged induction with lenalidomide affects the efficacy of stem cell collection among patients mobilized with cyclophosphamide and/or plerixafor. PATIENTS AND METHODS: This single center, retrospective study included patients who were treated with lenalidomide induction regimens, received mobilization with cyclophosphamide or plerixafor, and underwent apheresis in preparation for ASCT. 94 patients were included, 40 of whom received prolonged induction with >6 cycles of lenalidomide containing regimen. RESULTS: Patients who received prolonged induction were more likely to require >1 day of apheresis (38% vs. 15%; OR 3.45; P = .0154), and there was a significant correlation between the duration of lenalidomide treatment and the apheresis time required to collect sufficient cells for transplant (R2 = 0.06423, P = .0148). However, there was no significant difference between patients who received prolonged induction and those who did not with respect to CD34+ stem cell yields at completion of apheresis (9.99 vs. 10.46 cells/Kg, P = .5513) or on the first day of collection (8.29 vs. 9.59 cells/Kg, P = .1788). CONCLUSION: Among patients treated with >6 cycles of lenalidomide, mobilization augmented with cyclophosphamide and/or plerixafor will likely facilitate sufficient stem cell harvest to permit ASCT.


Subject(s)
Hematopoietic Stem Cell Transplantation , Heterocyclic Compounds , Lenalidomide , Multiple Myeloma , Benzylamines/therapeutic use , COVID-19 , Cyclams/therapeutic use , Cyclophosphamide/therapeutic use , Hematopoietic Stem Cell Mobilization/methods , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Humans , Lenalidomide/therapeutic use , Multiple Myeloma/drug therapy , Pandemics , Retrospective Studies , Transplantation, Autologous
4.
Biomolecules ; 11(1)2020 12 27.
Article in English | MEDLINE | ID: covidwho-1011421

ABSTRACT

In the context of the ongoing coronavirus disease 2019 (COVID-19) pandemic, numerous attempts have been made to discover new potential antiviral molecules against its causative agent, SARS-CoV-2, many of which focus on its main protease (Mpro). We hereby used two approaches based on molecular docking simulation to explore the interaction of four libraries of semisynthetic nitrogenous heterocyclic compounds with Mpro. Libraries L1 and L2 contain 52 synthetic derivatives of the natural compound 2-propylquinoline, whereas libraries L3 and L4 contain 65 compounds synthesized using the natural compound physostigmine as a precursor. Validation through redocking suggested that the rigid receptor and flexible receptor approaches used for docking were suitable to model the interaction of this type of compounds with the target protein, although the flexible approach seemed to provide a more realistic representation of interactions within the active site. Using empirical energy score thresholds, we selected 58 compounds from the four libraries with the most favorable energy estimates. Globally, favorable estimates were obtained for molecules with two or more substituents, putatively accommodating in three or more subsites within the Mpro active site. Our results pave the way for further experimental evaluation of the selected compounds as potential antiviral agents against SARS-CoV-2.


Subject(s)
Antiviral Agents/chemistry , COVID-19 Drug Treatment , COVID-19 , Coronavirus 3C Proteases , Heterocyclic Compounds/chemistry , Molecular Dynamics Simulation , Pandemics , Protease Inhibitors/chemistry , SARS-CoV-2/enzymology , Antiviral Agents/therapeutic use , COVID-19/epidemiology , Catalytic Domain , Coronavirus 3C Proteases/antagonists & inhibitors , Coronavirus 3C Proteases/chemistry , Heterocyclic Compounds/therapeutic use , Humans , Protease Inhibitors/therapeutic use
5.
Curr Org Synth ; 18(3): 248-269, 2021.
Article in English | MEDLINE | ID: covidwho-983623

ABSTRACT

Heterocyclic compounds containing the quinoline ring play a significant role in organic synthesis and therapeutic chemistry. Polyfunctionalized quinolines have attracted the attention of many research groups, especially those who work on drug discovery and development. These derivatives have been widely explored by the research biochemists and are reported to possess wide biological activities. This review focuses on the recent progress in the synthesis of heterocyclic compounds based-quinoline and their potential biological activities.


Subject(s)
Anti-Infective Agents/therapeutic use , Heterocyclic Compounds/therapeutic use , Quinolines/chemistry , Animals , Anti-Infective Agents/chemistry , Heterocyclic Compounds/chemistry , Humans
6.
Cells ; 9(6)2020 06 13.
Article in English | MEDLINE | ID: covidwho-603067

ABSTRACT

There is no vaccine or specific antiviral treatment for COVID-19, which is causing a global pandemic. One current focus is drug repurposing research, but those drugs have limited therapeutic efficacies and known adverse effects. The pathology of COVID-19 is essentially unknown. Without this understanding, it is challenging to discover a successful treatment to be approved for clinical use. This paper addresses several key biological processes of reactive oxygen, halogen and nitrogen species (ROS, RHS and RNS) that play crucial physiological roles in organisms from plants to humans. These include why superoxide dismutases, the enzymes to catalyze the formation of H2O2, are required for protecting ROS-induced injury in cell metabolism, why the amount of ROS/RNS produced by ionizing radiation at clinically relevant doses is ~1000 fold lower than the endogenous ROS/RNS level routinely produced in the cell and why a low level of endogenous RHS plays a crucial role in phagocytosis for immune defense. Herein we propose a plausible amplification mechanism in immune defense: ozone-depleting-like halogen cyclic reactions enhancing RHS effects are responsible for all the mentioned physiological functions, which are activated by H2O2 and deactivated by NO signaling molecule. Our results show that the reaction cycles can be repeated thousands of times and amplify the RHS pathogen-killing (defense) effects by 100,000 fold in phagocytosis, resembling the cyclic ozone-depleting reactions in the stratosphere. It is unraveled that H2O2 is a required protective signaling molecule (angel) in the defense system for human health and its dysfunction can cause many diseases or conditions such as autoimmune disorders, aging and cancer. We also identify a class of potent drugs for effective treatment of invading pathogens such as HIV and SARS-CoV-2 (COVID-19), cancer and other diseases, and provide a molecular mechanism of action of the drugs or candidates.


Subject(s)
Antiviral Agents/chemistry , Coronavirus Infections/drug therapy , Coronavirus Infections/immunology , Heterocyclic Compounds/therapeutic use , Hydrocarbons, Halogenated/therapeutic use , Pneumonia, Viral/drug therapy , Pneumonia, Viral/immunology , Animals , Antiviral Agents/therapeutic use , COVID-19 , Coronavirus Infections/metabolism , Humans , Hydrogen Peroxide/metabolism , Lysosomes/drug effects , Pandemics , Phagocytosis , Pneumonia, Viral/metabolism , Respiratory Burst/drug effects , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL